New molecular targets for cutaneous T-cell lymphoma therapy

There have been exciting developments in molecular targets for cutaneous T-cell lymphoma therapy, which have been enabled by new techniques such as next-generation sequencing. Here, Chalid Assaf, MD, PhD, of Helios Klinikum Krefeld, Krefeld, Germany, identifies several interesting signalling pathways, including NF-κB and PI3Kγ. Prof. Assaf highlights that these pathways need further analyses in order to be used for effective targeted therapies, and discusses several clinical trials that are underway. This interview was recorded at the European Organisation for the Research and Treatment of Cancer (EORTC) Cutaneous Lymphoma Task Force (CLTF) 2018 Congress, held in St. Gallen, Switzerland.